Radioiodine therapy for differentiated thyroid carcinoma.
Radioiodine (iodine 131) is an effective form of adjuvant therapy that is frequently underutilized. A review of our recent experience was undertaken to assess the role of this treatment modality in the routine management of thyroid carcinoma. Over a 2-year period, 29 patients received adjuvant iodine 131 therapy. Ten of these patients (35 percent) were found to have local or distant metastasis by iodine-131 scan, and 7 (24 percent) had a metastatic lesion not suspected by operative findings or chest radiography. A complete response was obtained in 70 percent of the patients with metastatic disease. This study supports more frequent use of adjuvant radioiodine therapy in the management of differentiated thyroid carcinoma.
Connor
C S
CS
Department of General Surgery, University of Kansas Medical Center, Kansas City 66103.
Thomas
J H
JH
Robinson
R G
RG
Preston
D F
DF
Hermreck
A S
AS
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000628:therapy
D007457:Iodine Radioisotopes